【作者】 王华庆； 刘霞； 刘贤明； 张会来； 李兰芳； 钱正子； 侯芸； 郝希山；

【Author】 Huaqing Wang,Xia Liu,Xianming Liu,Huilai Zhang,Lanfang Li,Zhengzi Qian,Yun Hou,Xishan Hao. The Department of Lymphoma,Cancer Institute and Hospital of Tianjin Medical University,Tianjin 300060,China

【机构】 天津医科大学附属肿瘤医院淋巴瘤科天津市肿瘤防治重点实验室；

【摘要】 目的:研究Bcl-2、Ki-67在恶性淋巴瘤(Malignant lymphoma,ML)组织中的表达以及与自体造血干细胞移植(autologous hematopoietic stem cell transplantation,AHSCT)预后的相关关系。方法:1.采用免疫组织化学(immunohistochemistry,IHC)法检测33例行AHSCT治疗的患者组织切片中Ki-67,Bcl-2的表达。并探讨Ki-67,Bcl-2的表达与预后的相关性。2.生存率统计采用Kaplan-Meier生存曲线,Log-rank检验,多因素分析采用Cox风险回归模型。结果:1.33例AHSCT治疗组,Bcl-2阳性表达组和阴性表达组移植后3年无病生存率分别为35.71%和88.89%(P<0.05);Ki-67阳性表达组和阴性表达组3年无病生存率分别为43.75%和85.71%(P<0.05),提示Bcl-2和Ki-67的表达与AHSCT的预后相关。2.Cox多因素分析显示,Ki-67和Bcl-2是影响ML患者AHSCT后无病生存的相关因素(P=0.0437)。结论:Bcl-2、Ki-67蛋白阳性表达的ML患者,AHSCT后易复发,可作为移植后预后判断的指标之一。Ki-67和Bcl-2是影响ML患者AHSCT无病生存的独立相关因素。更多还原

【Abstract】 Objective:To study the relationship between the expression of Bcl-2、Ki-67 and prognosis for patients given autologous hematopoietic stem cell transplantation(AHSCT) for malignant lymphoma(ML).Methods:1.Bcl-2、Ki-67 were measured by immunohistochemistry (IHC) on paraffin-embedded slices in 33 cases of ML who received AHSCT.2.Survival analysis was done by the Kaplan-Meier method and log-rank test.Multivariate analysis was carried out using Cox proportional hazard model.Results:1.For patients with ML who received AHSCT,the 3-year disease free survival(DFS) of Bcl-2(+) group was 35.71%,while that Bcl-2(-) group was 88.89%.There was significant difference of DFS between the two groups.Meanwhile,for these patients,the 3-year DFS of Ki-67(+) and Ki-67(-) were 43.75%and 85.71%,respectively(P<0.05).2. Multivariate analysis showed that the expression of Bcl-2 and Ki-67 were the independent prognostic factors.Conclusion:The expression of Bcl-2 and Ki-67 were closely related with relapse after AHSCT in patients with ML.They were useful molecular makers for predicting the prognosis of patients with ML after AHSCT.更多还原